Investigation of the transfer of septum microbial contamination by hypodermic needles by Eaton, Tim et al.
© EJPPS 2019      
 
 
 
 
EJPPS – European Journal of Parenteral and Pharmaceutical Sciences Volume 25 Issue 1 
https://www.ejpps.online/investigation-of-the-transfer-of-se 
https://doi.org/10.37521/ejpps/2501 
 
 
 
Investigation of the Transfer of Septum Microbial Contamination by Hypodermic Needles  
 
 
T Eaton      AstraZeneca, Macclesfield, UK 
L Ramscar     AstraZeneca, Macclesfield, UK 
J Cox              AstraZeneca, Macclesfield, UK 
W Whyte        James Watt Building South, University of Glasgow, UK 
 
 
Corresponding Author: Tim Eaton, Sterile Manufacturing Specialist 
                                          AstraZeneca,  
                                          UK Operations,  
                                          Silk Road Business Park, 
                                          Macclesfield 
                                          Cheshire. SK10 2NA 
                                          England 
                                        
 
                                          Email:         tim.eaton@astrazeneca.com          
                                          Telephone:  +44(0) 1625 514916 
 
 
 
 
 
© EJPPS 2019      
 
 
Investigation of the Transfer of Septum Microbial Contamination by a 
Hypodermic Needle  
 
 
T Eaton1 , L Ramscar1, J Cox1 and W Whyte2  
1 AstraZeneca, Macclesfield, UK  
2 James Watt Building South, University of Glasgow, UK 
 
 
Summary 
The likelihood of the transfer of microbial contamination from the surface of a vial septum into the 
vial liquid, by penetration of a hypodermic syringe needle, has been investigated. Experimental work 
was carried out with vials containing sterile microbial growth media and the use of needles of three 
different diameters. Three different concentrations of microbes on the surface of the vial septum 
(10, 100, and 1000) were used. Microbial contamination that was transferred into the growth media 
was determined by incubation of the vials following penetration of the septum by the needles. 
Contamination was detected in 87% of all the vials tested, and was generally found to increase as 
the concentration of septum challenge organisms and needle diameter increased. 
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1. Introduction 
The risk of infection in a patient from the administration of a pharmaceutical product into the 
bloodstream is dependent on the product being manufactured free of microbes, and any microbes 
introduced during manufacture being able to survive and grow in the product. Additionally, 
contamination on the surface of a vial septum may be introduced into the vial when it is pierced and, 
furthermore, skin microbes may be transferred when a needle passes through the skin. 
Information is available about the likelihood of microbial contamination during pharmaceutical 
product manufacturing and it is generally accepted that manufacturing carried out to the 
requirements of the EU GGMP 1, and other applicable authority guides, will ensure minimal levels of 
microbial contamination. The possibility of survival and growth of microbes in products 
contaminated during manufacturing has also been reported 2. The likelihood of the transfer of skin 
microbes into a patient during a subcutaneous injection, or taking blood from a vein, has been 
shown to occur on about 2% of occasions 3, 4. 
The penetration of a syringe needle through a vial rubber septum may transfer micro-organisms 
from the surface of the septum into the vial. If conditions are favourable, the microbial 
contamination may multiply, and cause infections in patients. To minimise this possibility, WHO 
guidelines 5 suggest a reduction of the concentration of septum microbes by swabbing with 70% 
alcohol, using gloves, and minimising the time for microbial proliferation by timely administration to 
the patient, and also avoiding the use of multidose vials. A key consideration associated with this risk 
is the likelihood of the transfer of the contamination through the septum into the vial. However, 
there appears to be little information available in the scientific literature about how easily this 
occurs. This has been investigated and reported in this article. 
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2. Experimental Methods 
Preparation of vials 
The vials used in the experiments were 30 ml capacity, with rubber septum seals secured by 
aluminium crimps. They were prepared with 20 ml of tryptone soya broth (Thermo Fisher Scientific) 
and sterilised in an autoclave using a fluids load sterilisation cycle. Under controlled conditions, the 
sterile vials were sealed into three separate layers of polythene bags and gamma irradiated (25 kGy). 
Samples of the tryptone soya broth (TSB) were removed and tested against a range of standard test 
micro-organisms and their ability to support microbial growth was confirmed. Utilising sequential 
removal of the three layers of polythene wrappings, 180 vials were aseptically transferred into a 
Class II microbiological safety cabinet. 
 
Syringe Preparation 
One hundred and eighty syringes were used for the experimental work. They were divided into three 
groups of 60, with each group having three different diameters of hypodermic needles (25, 18 and 
16 gauge). Shown in Table 1 is the gauge of the needles, along with their diameter, wall thickness, 
and surface area.  
 
 
Table 1 Sizes of hypodermic needles used in experiments 
Needle 
Gauge 
Outer Diameter 
(mm) 
Wall Thickness 
(mm) 
Needle Surface 
Area 
(mm
2
) 
16 1.651 0.229 2.21 
18 1.270 0.216 1.58 
25 0.5144 0.1270 0.35 
 
 
The syringes and needles were secured in three separate layers of polythene bags and gamma 
irradiated (25 kGy). Sixty sterilised syringes at each needle size, (a total of 180 syringes) were then 
aseptically transferred into the Class II microbiological safety cabinet.  
The needles with their gauge numbers and outside diameters (OD) are shown in Figure 1.  
 
 
25 Gauge         18 Gauge              16 Gauge 
OD 0.51 mm         OD 1.65 mm              OD 2.11 mm 
 
Figure 1 Syringes needles 
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Microbial Test Suspensions 
Microbial test suspensions were prepared at three different concentrations of 10, 100, and 1000 cfu 
per 0.1 ml. These suspensions contained two types of test microbes, which were; 
 
1. Bacillus atrophaeus (B. atrophaeus). ATCC 9372; a spore-forming organism that is able to survive 
adverse conditions and highly unlikely to die in the drying conditions that occurred during the 
experiments. 
2. Micrococcus luteus (M. luteus); a common Gram-positive skin organism that was isolated from the 
cleanroom manufacturing facilities at AZ, Macclesfield. 
 
Test Procedure 
The needle insertion zone of the vials was the ‘ribbed’ area of approximately 4 mm diameter      
(12.6 mm2 surface area), on the outer exposed surface of the septum seals, and these were equally 
contaminated with 0.1 ml of each of the six test suspensions. The six test suspensions included the 
two types of test organisms at each of the three concentrations. The septum seals, contaminated 
with the test suspension prior to drying, are shown in Figure 2. The test suspensions on the septum 
were then left in the Class II microbiological safety cabinet for 90 minutes to completely dry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Vial septum seals with 0.1 ml of microbial test suspension on the needle insertion zone 
 
The experiments were carried out in the Class II microbiological safety cabinet. Groups of 10 
vials, with three microbial concentrations of both test microbes on the vial septum, were tested with 
the different needle sizes. This was a total of 60 vials per needle size, and an overall total of 180 
vials. The septum needle insertion zone was penetrated by a needle, and the needle was submerged 
in the TSB to the same depth. One rinse of the syringe and needle with the TSB was carried out, and 
the needle withdrawn from the septum. All vials were then incubated at 32.50C (+ 1.50C) for five 
days and examined for microbial growth.  
Several control experiments were carried out. The experiment carried out to ascertain the 
amount of vial contamination from piercing of the septum was repeated, but without any 
contamination of the septum seals. Also, when any growth was found in the vials, it was identified. 
Finally, to confirm the number test microbes placed on the septum, tryptone soya agar plates 
(Becton Dickinson) were inoculated with 0.1 ml of the same suspension that was added to the 
septum surface and, after incubation, the number of microbial colonies counted. 
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Test Results 
Control results 
The control experiment without contaminating the septum with test microbes resulted in no 
microbial contamination of the TSB. Also, the control experiment that investigated the type of 
growth in the vials found the growth to always be the same as the test organism used. Finally, the 
number of microbes placed onto the septum, in different experimental conditions, is given in Table 
2. These results show that the concentrations were almost identical to the counts expected to have 
been added to the septum. 
 
Table 2 Number of microbes added to the vial septums  
Needle Gauge 
Experiment 
Microbial Test Challenge  
 
10 /septum 
 
100/septum  
 
1000/septum  
 
M. luteus B. atrophaeus M. luteus B. atrophaeus M. luteus B. atrophaeus 
16 6 8 91 96 1055 935 
18 11 13 89 122 990 1152 
25 11 13 89 122 990 1152 
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Growth after insertion of needle through the septum 
The results of the growth in vials caused by the two test microbes being injected through the septum 
and into vials are summarised in Table 3. 
 
 
Table 3 Septum microbial challenges and number of contaminated vials for each needle size 
Needle 
Gauge and 
Test Details 
Microbial test challenge on septum 
Number of vials with growth (out of 10) 
 
Average growth in 
vial according to 
needle gauge for all 
concentrations of 
test organisms 
10/septum 100/septum 1000/septum 
M. 
luteus 
B. 
atrophaeus 
M. 
luteus 
B. 
atrophaeus 
M. 
luteus 
B. 
atrophaeus 
16 gauge 9 9 10 10 10 9 
95% 
Average vial 
contamination 
per 
concentration of 
challenge 
organism 
90% 100% 95% 
18 gauge 7 7 10 8 10 10 
87% 
Average vial 
contamination 
per 
concentration of 
challenge 
organism 
70% 90% 100% 
25 gauge 8 5 9 9 10 7 
80% 
Average vial 
contamination 
per 
concentration of 
challenge 
organism 
65% 90% 85% 
Overall average 
vial 
contamination 
per 
concentration of 
challenge 
organisms for all 
needle sizes 
75% 93% 95% - 
 
It can be seen in Table 3 that 157 vials out of a total of 180 (87%) were contaminated. Bacillus 
atrophaeus is known to survive in dry conditions and would remain viable well past the end of the 
test suspension drying period. This organism was included in the testing as it was unsure to what 
extent Micrococcus luteus, a common human skin organism, was likely to survive the drying process 
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on the vial septum. However, the results indicate negligible differences in the recovery levels for 
both types of test organism, and so the results associated with both microbes were combined.  
The results in the last row of Table 3 indicate that there is, on average, for the each of the three 
different sizes of needles, a trend of increased vial contamination as the concentration of challenge 
microbes increases. It can be seen in the bottom row that the average vial recoveries were 75%, 93% 
and 95% for the 10, 100 and 1000 microbes on the septum surface. It can also be seen in the last 
column of Table 1 that for the three different challenges of test microbes, there is a general 
decrease in the number of contaminated vials as the needle size decreases; the average vial 
recoveries were 95%, 87% and 80% for the 16, 18 and 25 needle gauge sizes, respectively. It would, 
therefore, be reasonable to conclude that the higher the surface microbial challenge and the larger 
the contacting area of the needle, the greater the transfer of contamination through the septum. 
 
3. Discussion and Conclusions 
The transfer of microbial contamination from the surface of a vial septum into the associated vial, 
when the septum is penetrated by a needle, has been investigated experimentally. The septums 
were contaminated by different numbers of micro-organisms (10, 100 and 1000 per septum) and 
pierced with three different sizes of hypodermic needle (16, 18 and 24 gauge). The needles that 
passed through the septum were immersed in the sterile TSB in the vial, and the microbial 
contamination rate of the vials determined.  
For the each of the three different sizes of needles, it was found that the vial contamination rate 
increased as the concentration of challenge microbes on the septum surfaces increased, and the 
average rates were 75%, 93% and 95% for 10, 100, and 1000 microbes, respectively. There was also 
an increase in the number of contaminated vials with increasing needle size, with average 
contamination rates of 80%, 87%, and 95%, for the 25, 18 and 16 needle gauge sizes, respectively. 
Overall, it is concluded that the higher the surface microbial concentrations, and the larger the 
diameter of the needle, the greater the risk of transfer of the contamination through the septum.  
Test microbes were recovered in 65% of the vials when the lowest concentration of surface 
microbes (10 per septum) was present, and smallest sized needles (25 gauge) used. There is a 
reasonable likelihood that levels greater than 10 microbes will be found on vial septums after 
exposure to environmental contamination and handling. There is, therefore, a reasonable chance 
that the contents of a vial will be contaminated when its septum is pierced by a needle. These 
microbes will then be passed onto a patient during routine administration of pharmaceutical 
products.  
The risk of infection to a patient from the transfer of microbes on the septum will be greater in 
multidose vials, as more microbes can be introduced into the vial owing to repeated piercing of the 
septum, and the longer time the microbes have to multiply. However, in single dose vials where the 
content of the vial is injected immediately, microbial growth is not possible, and this will present a 
much reduced risk to the patient.  
Depending on the liquid formulation, micro-organisms that are deposited into the liquid in vials 
will either die, survive but not multiply, or multiply 2. The risk to patients (including those immuno-
suppressed) from an occasional micro-organism is small 6. Nevertheless, in formulations that provide 
nutrition for microbial growth, and are not sufficiently antimicrobial, microbes may multiply to a 
concentration as high as 107/ml 2. Therefore, some multi-dose vials could provide conditions which 
present a significant risk to the recipient. However, people can be resistant to micro-organisms 
introduced into their bloodstream, as occurs in normal life activities, such as when eating 4 for 
example. However, we consider the possibility of microbial growth in a vial to be a potential risk to a 
patient. 
In order to control the potential patient infection from contaminated vial septums, the World 
Health Organization (WHO) 5 recommends that multidose vials are used only if there is no 
alternative, and discarded within 24 hours of opening, or after the time recommended by the 
manufacturer, if the vial does not contain antimicrobial preservatives. However, it is worth noting 
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that some formulations containing preservatives will support growth of some micro-organisms of 
the type found in cleanrooms 2. 
Many vials are secured with a septum crimp that covers the full surface of the septum which 
ensures minimal levels of microbial contamination are maintained on the septum until it is removed 
prior to use. The WHO 5 also recommend that, even with single dose vials, the septum is wiped with 
70% alcohol (isopropyl alcohol or ethanol) on a swab or cotton-wool ball and allowing it to air dry 
before piercing the vial. The use of sterile gloves is also recommended. The use of 70% isopropyl 
alcohol to reduce surface microbial contamination on hard surfaces has been investigated 7 and 
confirmed to be effective. However, if the level of septum contamination is high, and the method of 
wiping ineffective, a risk may remain. 
If the likelihood of vial contamination by a needle passing through the vial’s septum is 
considered, as well as an injection passing skin microbes into the patient, it appears that surprisingly 
few adverse patient reactions have been reported. This is likely to be caused by the vial liquid 
formulations not supporting microbial growth, and administration a short period of time after 
preparation. Also, people have the ability to continually and successfully deal with surprisingly large 
doses of microbes that invade the bloodstream 4, and it is only when a substantial number of 
pathogens are introduced that there is a serious risk of infection. However, there is a lack of 
information about the degree of risk associated with these potential hazards, with scope for further 
research and understanding, which would be aided by the information reported in this article. 
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